Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.33
-0.01000-0.43%
Pre-Market: Mar 12, 4:05 AM EDT
Comments
Loading...
MEI Pharma Analyst Ratings and Price Targets | NASDAQ:MEIP | Benzinga
MEI Pharma Inc has a consensus price target of $22.27 based on the ratings of 7 analysts. The high is $80 issued by Brookline Capital on May 23, 2023. The low is $0.1 issued by Jefferies on February 8, 2023. The 3 most-recent analyst ratings were released by Stifel on April 12, 2024, February 14, 2024, and September 27, 2023, respectively. With an average price target of $7.67 between Stifel, there's an implied 229.04% upside for MEI Pharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Brookline Capital
HC Wainwright & Co.
Jefferies
1calculated from analyst ratings
Analyst Ratings for MEI Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/23/2024 | Buy Now | — | Laidlaw & Co. | Yale Jen22% | — | Downgrade | Buy → Hold | Get Alert |
| 04/12/2024 | Buy Now | 200.43% | Stifel | Stephen Willey52% | $7 → $7 | Maintains | Hold | Get Alert |
| 02/14/2024 | Buy Now | 200.43% | Stifel | Stephen Willey52% | $8 → $7 | Maintains | Hold | Get Alert |
| 09/27/2023 | Buy Now | 286.27% | Stifel | Stephen Willey52% | $10 → $9 | Maintains | Hold | Get Alert |
| 05/23/2023 | Buy Now | 3333.48% | Brookline Capital | Leah Cann48% | → $80 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 329.18% | Stifel | Stephen Willey52% | $0.5 → $10 | Maintains | Hold | Get Alert |
| 02/13/2023 | Buy Now | -14.16% | HC Wainwright & Co. | Andrew Fein57% | $100 → $40 | Maintains | Buy | Get Alert |
| 02/08/2023 | Buy Now | -95.71% | Jefferies | Chris Howerton63% | $8 → $2 | Downgrade | Hold → Underperform | Get Alert |
| 12/06/2022 | Buy Now | — | BTIG | Justin Zelin40% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/06/2022 | Buy Now | — | Truist Securities | Robyn Karnauskas55% | — | Downgrade | Buy → Hold | Get Alert |
FAQ
What is the target price for MEI Pharma (MEIP) stock?
The latest price target for MEI Pharma (NASDAQ:MEIP) was reported by Laidlaw & Co. on July 23, 2024. The analyst firm set a price target for $0.00 expecting MEIP to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for MEI Pharma (MEIP)?
The latest analyst rating for MEI Pharma (NASDAQ:MEIP) was provided by Laidlaw & Co., and MEI Pharma downgraded their hold rating.
When was the last upgrade for MEI Pharma (MEIP)?
There is no last upgrade for MEI Pharma
When was the last downgrade for MEI Pharma (MEIP)?
The last downgrade for MEI Pharma Inc happened on July 23, 2024 when Laidlaw & Co. changed their price target from N/A to N/A for MEI Pharma Inc.
When is the next analyst rating going to be posted or updated for MEI Pharma (MEIP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MEI Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MEI Pharma was filed on July 23, 2024 so you should expect the next rating to be made available sometime around July 23, 2025.
Is the Analyst Rating MEI Pharma (MEIP) correct?
While ratings are subjective and will change, the latest MEI Pharma (MEIP) rating was a downgraded with a price target of $0.00 to $0.00. The current price MEI Pharma (MEIP) is trading at is $2.33, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.